Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 11/20 | 1.00 |
| ▸ | HTR1A | P08908 | 9/20 | 1.00 |
| ▸ | HTR2C | P28335 | 8/20 | 1.00 |
| ▸ | HTR2A | P28223 | 8/20 | 1.00 |
| ▸ | HTR1B | P28222 | 8/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | HTR6 | P50406 | 5/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 1.00 |
| ▸ | HTR3B | O95264 | 4/20 | 1.00 |
| ▸ | HTR1E | P28566 | 4/20 | 1.00 |
| ▸ | HTR1F | P30939 | 4/20 | 1.00 |
| ▸ | HTR7 | P34969 | 4/20 | 1.00 |
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | HTR5A | P47898 | 4/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 4/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 1.00 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970981 | 1.00 | HTR1D (1.00) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL23069130 | 0.86 | HTR1D (0.75) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL2409566 | 0.85 | HTR1D (0.73) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL20970979 | 0.84 | HTR1D (0.72) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL29633043 | 0.84 | HTR1D (0.72) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL20970917 | 0.82 | HTR1D (0.69) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL30249112 | 0.82 | HTR1D (0.69) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL25747780 | 0.82 | HTR1D (0.86) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL1973250 | 0.80 | HTR2A (0.66) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL32669398 | 0.80 | HTR1A (0.66) | HTR1DHTR1AHTR2CHTR2AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2024251807-A1 | COMPANION ANIMAL TREATMENTS | CYBIN IRL LIMITED (IE) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024231331-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | CYBIN IRL LIMITED (IE) | 2024-11-14 | — | — | WO | disclosed |
| EP-4452986-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | Kuleon LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4392027-A2 | FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023225043-A1 | TRICYCLIC AND TETRACYCLIC SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023028092-A2 | FLUORINATED EMPATHOGENS | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | HTR1D 11/4885HTR1A 4/4885HTR2C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.